Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emma Clark

Showing results (41-50 of 93) with videos related to

Pageof 10
Sort By:
Cancer Chemotherapy and Pharmacology|September 4, 2013
Exposure-response analysis of pertuzumab in HER2-positive metastatic breast cancer: absence of effect on QTc prolongation and other ECG parametersAmit Garg, Jing Li, Emma Clark, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2007
A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancerIan E Smith, Geraldine Walsh, Anthony Skene, et al.
European Urology Open Science|July 13, 2023
Photodynamic Diagnosis-guided Transurethral Resection of Bladder Tumour in Participants with a First Suspected Diagnosis of Intermediate- or High-risk Non-muscle-invasive Bladder Cancer: Cost-effectiveness Analysis Alongside a Randomised Controlled TrialGe Yu, Stephen Rice, Rakesh Heer, et al.
The Journal of Antimicrobial Chemotherapy|September 25, 2021
The use of first-generation cephalosporin antibiotics, cefalexin and cefradine, is not associated with induction of simulated Clostridioides difficile infectionAnthony M Buckley, Ines B Moura, James Altringham, et al.
The Journal of Antimicrobial Chemotherapy|September 15, 2020
Eravacycline, a novel tetracycline derivative, does not induce Clostridioides difficile infection in an in vitro human gut modelAnthony M Buckley, James Altringham, Emma Clark, et al.
The Oncologist|March 12, 2013
Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III studySandra M Swain, Michael S Ewer, Javier Cortés, et al.
Health Technology Assessment (Winchester, England)|July 2, 2016
The feasibility of a randomised controlled trial of physiotherapy for adults with joint hypermobility syndromeShea Palmer, Fiona Cramp, Emma Clark, et al.
Pediatrics|June 1, 2025
Feasibility and Acceptability of Recommending HPV Vaccine at Ages 9-10 YearsCaroline K Tietbohl, Dennis Gurfinkel, Danielle Duran, et al.
Jac-Antimicrobial Resistance|July 24, 2024
Antimicrobial susceptibility in <i>Clostridioides difficile</i> varies according to European region and isolate sourceJane Freeman, Virginie Viprey, Duncan Ewin, et al.
The Lancet. Oncology|December 15, 2016
Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA studyStephen J Luen, Roberto Salgado, Stephen Fox, et al.
Pageof 10

Showing results (41-50 of 93) with videos related to

Sort By:
Pageof 10
Cancer Chemotherapy and Pharmacology|September 4, 2013
Exposure-response analysis of pertuzumab in HER2-positive metastatic breast cancer: absence of effect on QTc prolongation and other ECG parametersAmit Garg, Jing Li, Emma Clark, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2007
A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancerIan E Smith, Geraldine Walsh, Anthony Skene, et al.
European Urology Open Science|July 13, 2023
Photodynamic Diagnosis-guided Transurethral Resection of Bladder Tumour in Participants with a First Suspected Diagnosis of Intermediate- or High-risk Non-muscle-invasive Bladder Cancer: Cost-effectiveness Analysis Alongside a Randomised Controlled TrialGe Yu, Stephen Rice, Rakesh Heer, et al.
The Journal of Antimicrobial Chemotherapy|September 25, 2021
The use of first-generation cephalosporin antibiotics, cefalexin and cefradine, is not associated with induction of simulated Clostridioides difficile infectionAnthony M Buckley, Ines B Moura, James Altringham, et al.
The Journal of Antimicrobial Chemotherapy|September 15, 2020
Eravacycline, a novel tetracycline derivative, does not induce Clostridioides difficile infection in an in vitro human gut modelAnthony M Buckley, James Altringham, Emma Clark, et al.
The Oncologist|March 12, 2013
Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III studySandra M Swain, Michael S Ewer, Javier Cortés, et al.
Health Technology Assessment (Winchester, England)|July 2, 2016
The feasibility of a randomised controlled trial of physiotherapy for adults with joint hypermobility syndromeShea Palmer, Fiona Cramp, Emma Clark, et al.
Pediatrics|June 1, 2025
Feasibility and Acceptability of Recommending HPV Vaccine at Ages 9-10 YearsCaroline K Tietbohl, Dennis Gurfinkel, Danielle Duran, et al.
Jac-Antimicrobial Resistance|July 24, 2024
Antimicrobial susceptibility in <i>Clostridioides difficile</i> varies according to European region and isolate sourceJane Freeman, Virginie Viprey, Duncan Ewin, et al.
The Lancet. Oncology|December 15, 2016
Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA studyStephen J Luen, Roberto Salgado, Stephen Fox, et al.
Pageof 10